[
  {
    "ts": null,
    "headline": "Token Security Extends Identity Governance to Autonomous AI with Launch of AI Agent Identity Lifecycle Management",
    "summary": "For the first time, security, IT and IAM teams can manage AI agent identities from discovery to deprovisioning to eliminate blind spots, enforce least privilege, and secure the next evolution of identity and access management NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Token Security, the leader in Agentic Identity security, today announced new AI Agent Identity Lifecycle Management capabilities which empower enterprises to discover, govern, manage, and secure the rapidly growing population of A",
    "url": "https://finnhub.io/api/news?id=9266fd884709e34e3ed6ee751f0582e4e0546cb3e0721ea7397d58f5ad6839bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763560980,
      "headline": "Token Security Extends Identity Governance to Autonomous AI with Launch of AI Agent Identity Lifecycle Management",
      "id": 137546958,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "For the first time, security, IT and IAM teams can manage AI agent identities from discovery to deprovisioning to eliminate blind spots, enforce least privilege, and secure the next evolution of identity and access management NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Token Security, the leader in Agentic Identity security, today announced new AI Agent Identity Lifecycle Management capabilities which empower enterprises to discover, govern, manage, and secure the rapidly growing population of A",
      "url": "https://finnhub.io/api/news?id=9266fd884709e34e3ed6ee751f0582e4e0546cb3e0721ea7397d58f5ad6839bc"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities",
    "summary": "New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November ...",
    "url": "https://finnhub.io/api/news?id=f5c769ccb8141c327882573e3c69708d1633e83bb8077e9e60ab6b10a53920ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763553600,
      "headline": "Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities",
      "id": 137546959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November ...",
      "url": "https://finnhub.io/api/news?id=f5c769ccb8141c327882573e3c69708d1633e83bb8077e9e60ab6b10a53920ad"
    }
  },
  {
    "ts": null,
    "headline": "Alkermes escalates bidding war; US biotech risks ‘falling behind’ China",
    "summary": "A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.",
    "url": "https://finnhub.io/api/news?id=30335b03a4fc0a7c4aff8ec0568be693fb2b7bdafc4ac61489c47bfcda5042c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763548380,
      "headline": "Alkermes escalates bidding war; US biotech risks ‘falling behind’ China",
      "id": 137548671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.",
      "url": "https://finnhub.io/api/news?id=30335b03a4fc0a7c4aff8ec0568be693fb2b7bdafc4ac61489c47bfcda5042c2"
    }
  },
  {
    "ts": null,
    "headline": "Is Moderna (MRNA) Undervalued? Examining the Latest Valuation Narrative and Investor Sentiment",
    "summary": "Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up the company's revenue growth alongside its ongoing net losses, especially as the biotech sector faces headwinds. See our latest analysis for Moderna. After a tough year, Moderna’s share price sits at $24.92, down more than 40% year-to-date, while its total shareholder return over the past 12 months is also in firmly negative territory. Momentum has faded as investors...",
    "url": "https://finnhub.io/api/news?id=7f4af781a63c5425a4df76780c7860595c70cc78787719be4d5fe373d1100b50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763526581,
      "headline": "Is Moderna (MRNA) Undervalued? Examining the Latest Valuation Narrative and Investor Sentiment",
      "id": 137543869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up the company's revenue growth alongside its ongoing net losses, especially as the biotech sector faces headwinds. See our latest analysis for Moderna. After a tough year, Moderna’s share price sits at $24.92, down more than 40% year-to-date, while its total shareholder return over the past 12 months is also in firmly negative territory. Momentum has faded as investors...",
      "url": "https://finnhub.io/api/news?id=7f4af781a63c5425a4df76780c7860595c70cc78787719be4d5fe373d1100b50"
    }
  }
]